Recruiting

Intra-articular Injections

Sponsor:

Rush University Medical Center

Code:

NCT04949087

Conditions

Arthritis Shoulder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Glenohumeral Injection

Study Details

Brief summary:

The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This study will help elucidate the therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this patient population.

Conditions

Arthritis Shoulder

Study ID

NCT04949087

Start date

Mar 13, 2023

Status verified date

Feb, 2026

Completion date

Jan, 2028

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient ≥18y.o. of age
  • Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been previously diagnosed on radiographs and clinical evaluation.
  • Baseline pain level of VAS >4

Exclusion Criteria:

  • Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, post-traumatic arthritis)
  • Ipsilateral shoulder surgery within 1 year
  • Any glenohumeral joint injection within 3 months
  • Allergy to lidocaine
  • Known pregnancy
  • Workers compensation case regarding shoulder

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Corticosteroid Injection Group

80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection

active comparator: Platelet-Rich Plasma Injection Group

15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP

Interventions

Glenohumeral Injection

Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.

Primary outcome measure

  • Visual Analog Scale-Pain (VAS) [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Carla M Edwards, PhD

312.563.5735carla_edwards@rush.edu

Locations

Rush University Medical Center

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Carla M Edwards, PhD

312-563-5735carla_edwards@rush.edu

Principal Investigator:

Adam Yanke, MD, PhD

More Information

Sponsor

Rush University Medical Center

Last update posted

Feb 17, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Rush University Medical Center on 2026-02-17.